Ashland (ASH)

• Market cap: $2.37B
• 1 day: -0.44%
• 5 days: -2.12%
• 1 month: -10.97%
• 3 months: -31.30%
• 6 months: -42.06%
• Year to date: -27.93%
• 1 year: -47.47%
• 5 years: -6.93%
• 10 years: -60.40%
• Sector: Materials
• Industry: Specialty Chemicals

About: Ashland Inc is a world-wide specialty materials company that serves a wide range of industrial markets. The company has a business-centric operating model and is organized into four distinct segments: life sciences, personal care, specialty additives, and intermediates. Key customers for the firm include pharmaceutical companies and manufacturers of personal care products, food and beverages, and nutraceuticals and supplements. The life sciences segment derives maximum revenue. The company generates its sales from North America, Europe, Asia Pacific, and Latin America, and Others.

Employees: 3,200

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

4.0% more ownership

Funds ownership: 90.47% [Q3] → 94.47% (+4.0%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]

6% less repeat investments, than reductions

Existing positions increased: 119 | Existing positions reduced: 127

7% less first-time investments, than exits

New positions opened: 54 | Existing positions closed: 58

3% less funds holding

Funds holding: 364 [Q3] → 353 (-11) [Q4]

17% less capital invested

Capital invested by funds: $3.84B [Q3] → $3.18B (-$659M) [Q4]

62% less call options, than puts

Call options by funds: $2.81M | Put options by funds: $7.38M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $58 15% upside
• Avg. target: $74 47% upside
• High target: $93 85% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Wells Fargo Michael Sison 21% 1-year accuracy 11 / 53 met price target	15% upside $58	Overweight Maintained	9 Apr 2025
JP Morgan Jeffrey Zekauskas 24% 1-year accuracy 11 / 45 met price target	41% upside $71	Overweight Upgraded	26 Mar 2025
UBS Joshua Spector 25% 1-year accuracy 13 / 52 met price target	85% upside $93	Buy Maintained	29 Jan 2025